59,200 Shares in Palvella Therapeutics, Inc. $PVLA Acquired by Artia Global Partners LP

Artia Global Partners LP purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 59,200 shares of the company’s stock, valued at approximately $6,196,000. Palvella Therapeutics comprises about 0.9% of Artia Global Partners LP’s holdings, making the stock its 20th largest holding. Artia Global Partners LP owned 0.50% of Palvella Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. MPM Bioimpact LLC raised its stake in shares of Palvella Therapeutics by 205.2% during the fourth quarter. MPM Bioimpact LLC now owns 205,745 shares of the company’s stock worth $21,535,000 after buying an additional 138,322 shares during the last quarter. First Light Asset Management LLC increased its stake in Palvella Therapeutics by 30.9% in the fourth quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock valued at $74,226,000 after purchasing an additional 167,597 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after purchasing an additional 433 shares in the last quarter. California State Teachers Retirement System increased its stake in Palvella Therapeutics by 1,512.8% in the fourth quarter. California State Teachers Retirement System now owns 6,919 shares of the company’s stock valued at $724,000 after purchasing an additional 6,490 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Palvella Therapeutics by 116.4% in the fourth quarter. Russell Investments Group Ltd. now owns 1,229 shares of the company’s stock valued at $129,000 after purchasing an additional 661 shares in the last quarter. 40.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on PVLA shares. Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital reaffirmed a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Mizuho upped their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Stock Up 2.3%

Shares of PVLA stock opened at $112.63 on Thursday. The firm has a fifty day moving average of $118.97 and a 200-day moving average of $108.85. Palvella Therapeutics, Inc. has a 12-month low of $20.20 and a 12-month high of $151.18. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of -27.01 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, equities analysts expect that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.